NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) approved inducement equity awards for two non-executive hires on April 1, 2026 under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).

The grants total 15,000 stock options (exercise price $32.81) and 3,200 restricted stock units, with multi-year vesting schedules tied to continued service.

AI-generated analysis. Not financial advice.

News Market Reaction – NAMSW

+11.58%

1 alert

+11.58% News Effect

On the day this news was published, NAMSW gained 11.58%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options granted: 15,000 shares Option exercise price: $32.81 per share Option vesting schedule: 25% after 1 year, then 36 monthly installments +5 more

8 metrics

Inducement options granted 15,000 shares Aggregate options to two non-executive new hires

Option exercise price $32.81 per share Closing market price on April 1, 2026 grant date

Option vesting schedule 25% after 1 year, then 36 monthly installments Four-year vesting subject to continued service

RSUs granted 3,200 shares Aggregate restricted stock units to two non-executive hires

RSU vesting schedule One-third annually over 3 years Vesting on 1-, 2-, and 3-year anniversaries

Price move 8.85% 1-day move prior to this news

Relative volume 4.42x Today vs 20-day average volume

52-week range position -29.14% vs high; 289.91% vs low Price relative to 52-week high/low before news

Market Reality Check

Price: $24.26 Vol: Volume 9,174 is 4.42x the...

high vol

$24.26 Last Close

Volume Volume 9,174 is 4.42x the 20-day average of 2,075, indicating elevated trading interest ahead of this routine compensation update. high

Technical At $21.25, shares trade above the $14.68 200-day moving average, reflecting a pre-existing upward trend into this announcement.

Peers on Argus

NAMSW gained 8.85% with elevated volume, while several warrant peers in Pharmace...

NAMSW gained 8.85% with elevated volume, while several warrant peers in Pharmaceutical Preparations also showed gains (e.g., KTTAW up 112.12%, DRMAW up 4.71%, ESLAW up 7%). However, the momentum scanner did not flag a coordinated sector move, suggesting stock-specific dynamics.

Historical Context

5 past events · Latest: Mar 06 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 06	Inducement grants	Neutral	-0.8%	Small inducement option and RSU awards for two non-executive hires.
Feb 18	Earnings and update	Positive	+12.0%	Full-year 2025 results with strong cash, accepted MAAs, and advancing Phase 3 trials.
Feb 06	Inducement grants	Neutral	+10.8%	Inducement options for 217,000 shares to new hires at set exercise price.
Feb 04	Conference appearance	Neutral	+7.0%	Participation in Guggenheim biotech summit virtual fireside chat.
Jan 09	Strategic update	Positive	-15.4%	2025 achievements and 2026 priorities for obicetrapib including EMA decision timing.

Pattern Detected

Routine news (inducement grants, conferences) has sometimes coincided with sizable upside moves, but there are also instances of sharp declines following positive strategic updates, indicating mixed and event-dependent reactions.

Recent Company History

Over recent months, NewAmsterdam has mixed routine corporate actions with significant strategic updates. Inducement equity grants were reported on Feb 6, 2026 and Mar 6, 2026, both tied to non-executive hires under the 2024 Inducement Plan. A Guggenheim biotech summit appearance on Feb 4, 2026 coincided with a notable gain. Full-year 2025 results on Feb 18, 2026 highlighted substantial cash of $728.9M and ongoing Phase 3 programs, with a positive price reaction. Conversely, a January 2026 progress update on obicetrapib accompanied a sharp selloff, underscoring inconsistent responses to positive milestones.

Market Pulse Summary

The stock surged +11.6% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +11.6% in the session following this news. A strong positive reaction aligns with the stock’s history of sizeable moves around even routine corporate updates. The inducement grants cover only 15,000 options and 3,200 RSUs, a modest issuance that mainly formalizes compensation for new hires. With price already 289.91% above the 52-week low and trading above the $14.68 200-day moving average, investors evaluating sustainability would consider prior instances where upbeat corporate news preceded both rallies and sharp pullbacks.

Key Terms

nasdaq listing rule 5635(c)(4), inducement share options, exercise price, restricted stock units, +2 more

6 terms

nasdaq listing rule 5635(c)(4) regulatory

"approved the grant of inducement share options ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement share options financial

"approved the grant of inducement share options covering an aggregate of 15,000 of NewAmsterdam’s ordinary shares"

Inducement share options are stock options granted to a new hire as a special incentive to join a company, issued outside the company’s standard employee share plans. For investors, they matter because they create potential future dilution of existing shares and represent a cash‑free form of compensation that signals how much the company values attracting particular talent—like offering a signing bonus paid in future ownership rather than cash.

exercise price financial

"The share options have an exercise price per share equal to $32.81"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

restricted stock units financial

"approved the grant of restricted stock units covering an aggregate of 3,200 of NewAmsterdam’s ordinary shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

option award agreement financial

"subject to the terms and conditions of an option award agreement covering the grant."

A written contract that grants an individual the right to buy company shares at a set price under specific conditions, like how many options they get, when they can exercise them, and when they expire. Think of it like a ticket that becomes valid only after certain milestones; it matters to investors because these agreements affect how many shares may enter the market, management incentives, and a company’s future earnings per share and dilution.

AI-generated analysis. Not financial advice.

NAARDEN, the Netherlands and MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 15,000 of NewAmsterdam’s ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price per share equal to $32.81, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on April 1, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.

The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 3,200 of NewAmsterdam’s ordinary shares to two non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units were granted on April 1, 2026. The restricted stock units will vest over three years, with one-third of the restricted stock units vesting on each of the one-year, two-year and three-year anniversaries of the applicable vesting commencement date, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The restricted stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the grant.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

FAQ

What equity awards did NewAmsterdam (NAMS) grant on April 1, 2026?

NewAmsterdam granted 15,000 stock options and 3,200 restricted stock units to two non-executive hires. According to the company, the options carry an exercise price of $32.81 and the RSUs and options vest over multi-year schedules tied to continued service.

What is the exercise price of the NAMS inducement options and how was it set?

The exercise price for the inducement options is $32.81, equal to the April 1, 2026 closing price. According to the company, that closing market price on Nasdaq set the per-share exercise price for the options granted.

How do the NAMS stock options vest for the April 1, 2026 grants?

The options vest over four years with 25% after one year, then monthly for 36 months. According to the company, vesting is subject to each employee's continued service on each vesting date under the 2024 Inducement Plan.

What is the vesting schedule for the 3,200 RSUs granted by NewAmsterdam (NAMS)?

The 3,200 restricted stock units vest over three years with one-third each year. According to the company, each tranche vests on the one-, two- and three-year anniversaries, subject to continued employment and award agreement terms.

Under what plan and Nasdaq rule were the NAMS inducement awards approved?

The grants were approved under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). According to the company, the Compensation Committee approved the inducement awards as material to the hires' acceptance of employment.